ArticleNeoplasia (New York, N.Y.)2013

Quantitative analysis of [11C]-erlotinib PET demonstrates specific binding for activating mutations of the EGFR kinase domain.

J Ryan Petrulli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.